Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
46 hedge funds and large institutions have $68.1M invested in Agile Therapeutics in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 13 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
139% more capital invested
Capital invested by funds: $28.5M → $68.1M (+$39.5M)
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
95% more call options, than puts
Call options by funds: $758K | Put options by funds: $389K
39% more funds holding
Funds holding: 33 → 46 (+13)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$2.08M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.55M |
| 3 |
Renaissance Technologies
New York
|
+$1.46M |
| 4 |
BlackRock
New York
|
+$1.38M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$573K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$1.89M |
| 2 |
6CM
683 Capital Management
New York
|
-$527K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$511K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$195K |
| 5 |
Millennium Management
New York
|
-$73.3K |
AGRX Hedge Fund Activity: Q4 2019 in Review
46 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2019, worth a combined $68.1M — up 139% from $28.5M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AGRX positions and 13 closed out — a net gain of 13 holders — while 11 added to existing stakes and 3 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $2.08M. The largest seller was Deerfield Management, exiting entirely with an estimated $1.89M sold.
- 46 institutional investors held Agile Therapeutics (AGRX) as of Q4 2019, up from 33 in Q3 2019.
- Funds reported $68.1M of Agile Therapeutics stock for Q4 2019, up 139% quarter-over-quarter.
- 26 funds opened new Agile Therapeutics positions in Q4 2019 and 13 closed out, a net change of +13 holders.
- The largest Agile Therapeutics buyer in Q4 2019 was Perceptive Advisors, an estimated $2.08M added.
- The largest Agile Therapeutics seller in Q4 2019 was Deerfield Management, an estimated $1.89M sold.
Based on aggregated 13F filings for Q4 2019.